About: What Solid Organ Transplant Healthcare Providers should know about Renin‐Angiotensin‐Aldosterone System Inhibitors and COVID‐19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: What Solid Organ Transplant Healthcare Providers should know about Renin‐Angiotensin‐Aldosterone System Inhibitors and COVID‐19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	What Solid Organ Transplant Healthcare Providers should know about Renin‐Angiotensin‐Aldosterone System Inhibitors and COVID‐19
Creator	Wong, Y Brubaker, Aleah Wang, Aileen Melcher, Marc Sunnie, Affiliations Taiwo, Adetokunbo Wong, Sunnie
Source	Medline; PMC
abstract	The data on the outcomes of solid organ transplant recipients who have contracted coronavirus disease 2019 (COVID‐19) are still emerging. Kidney transplant recipients are commonly prescribed renin‐angiotensin‐aldosterone system (AAS) inhibitors given the prevalence of hypertension, diabetes, and cardiovascular disease. As the angiotensin‐converting enzyme 2 (ACE2) facilitates the entry of coronaviruses into target cells, there have been hypotheses that preexisting use of Renin‐Angiotensin‐Aldosterone System (RAAS) inhibitors may increase the risk of developing severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. Given the common use of RAAS inhibitors among solid organ transplant recipients, we sought to review the RAAS cascade, the mechanism of SARS‐CoV‐2 entry, and pertinent data related to the effect of RAAS inhibitors on ACE2 to guide management of solid organ transplant recipients during the COVID‐19 pandemic. At present there is no clear evidence to support the discontinuation of RAAS inhibitors in solid organ transplant recipients during the COVID‐19 pandemic.
has issue date	2020-05-23(xsd:dateTime)
bibo:doi	10.1111/ctr.13991
bibo:pmid	32446267
has license	no-cc
sha1sum (hex)	09b2036eba6ba6a828fecc57c7ba7ff7ff7d9dcf
schema:url	https://doi.org/10.1111/ctr.13991
resource representing a document's title	What Solid Organ Transplant Healthcare Providers should know about Renin‐Angiotensin‐Aldosterone System Inhibitors and COVID‐19
has PubMed Central identifier	PMC7267091
has PubMed identifier	32446267
schema:publication	Clin Transplant
resource representing a document's body	covid:09b2036eba6ba6a828fecc57c7ba7ff7ff7d9dcf#body_text
is schema:about of	named entity 'pandemic' named entity 'coronaviruses' named entity 'data' named entity 'Title' named entity 'Inhibitors' named entity 'organ transplant' named entity 'prevalence' named entity 'emerging' named entity 'facilitates' named entity 'inhibitors' named entity 'developing' named entity 'management' named entity 'mechanism' named entity 'inhibitors' named entity 'coronavirus disease 2019' named entity 'solid organ transplant' named entity 'Kidney transplant' named entity 'COVID-19 pandemic' named entity 'solid organ transplant' named entity 'renin-angiotensin-aldosterone' named entity 'solid organ transplant' named entity 'hypertension' named entity 'Healthcare Providers' named entity 'RAAS' named entity 'Transplant Recipients' named entity 'Aldosterone' named entity 'COVID' named entity 'Renin-Angiotensin' named entity 'Solid Organ Transplant' named entity 'The' named entity 'ACEi' named entity 'RAAS' named entity 'homology' named entity 'cohort study' named entity 'Italy' named entity 'ARBs' named entity 'RAAS' named entity 'COVID-19 pandemic' named entity 'Ang II' named entity 'solid organ transplant' named entity 'cardiovascular disease' named entity 'metalloprotease' named entity 'ACE2' named entity 'Ang II' named entity 'ACEi' named entity 'ACE2' named entity 'cardiac tissue' named entity 'membrane-bound' named entity 'angiotensin II' named entity 'endothelial cell' named entity 'coronavirus disease 2019' named entity 'angiotensin II' named entity 'angiotensin-converting enzyme 2' named entity 'COVID' named entity 'Spain' named entity 'coronaviruses' named entity 'ACE2' named entity 'angiotensin' named entity 'ACE inhibitors' named entity 'ACE' named entity 'ACE2' named entity 'SARS-CoV' named entity 'renin' named entity 'ACE2' named entity 'infection' named entity 'membrane-bound' named entity 'angiotensin' named entity 'myocarditis' named entity 'angiotensinogen' named entity 'peptide' named entity 'transmembrane' named entity 'ACE2' named entity 'AT1R' named entity 'interact' named entity 'ARBs'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software